北京若生智能科技有限公司
Drug Database
PR

prednisolone

✓ Approved

Takeda · NR3C1 · 小分子

什么是 prednisolone？

prednisolone 是一种小分子，由Takeda研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

公司Takeda
药物类别小分子
分子靶点NR3C1
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Takeda

作用机制

分子靶点

prednisolone 作用于 1 个分子靶点：

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

prednisolone 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Plasma cell myeloma✓ Approved

相关研究文献

PubMedBMC ophthalmology2026-10-27

Short-term outcomes associated with oral prednisolone versus posterior sub-Tenon triamcinolone acetonide in acute ocular Vogt-Koyanagi-Harada disease.

Saad Ehab Mohamed Elsayed EME, Abouelela Mohamed I MI, Elsayed Mohamed Anany MA

To describe short-term clinical and anatomical outcomes associated with oral prednisolone and posterior sub-Tenon triamcinolone acetonide as initial corticosteroid-based treatment strategies in acute ocular Vogt-Koyanagi-Harada Disease (VKH). This retrospective comparative cohort study included 30 treatment-naïve patients (60 eyes) with acute ocular VKH treated at a tertiary referral center between January 2021 and December 2025. Patients were classified using a study-specific two-tier designation (definite or probable VKH) derived from the 2001 Revised Diagnostic Criteria. Treatment assignment (oral prednisolone, n = 15, 1.0 mg/kg/day tapered over 3-6 weeks; or PST/STA, n = 15) was guided by clinical severity and systemic involvement. The primary outcome was complete clinical and anatomical ocular control at 3 months, defined as absence of clinically active intraocular inflammation, resolution of subretinal fluid on OCT, and stable or improved BCVA. Secondary outcomes included BCVA over 6 months, OCT-based anatomical recovery, recurrence rates, rescue therapy requirement, and adverse events. Resolution of subretinal fluid was assessed qualitatively on OCT as complete disappearance of the subretinal fluid pocket, with central macular thickness (CMT) recorded in parallel as a supportive structural measure. Statistical analyses included the independent and paired t-tests, two-sided Fisher's exact test, and Kaplan-Meier analysis with the log-rank test. At 3 months, complete clinical and anatomical ocular control was achieved in 12/15 (80.0%) patients receiving prednisolone and 11/15 (73.3%) receiving PST/STA (p = 1.00, Fisher's exact test). Resolution of subretinal fluid occurred in 86.7% (13/15) and 80.0% (12/15) of patients, respectively (p = 1.00, Fisher's exact test). Mean BCVA improved in both groups over 6 months, with no statistically significant between-group difference. OCT analysis demonstrated no statistically significant between-group differences in the assessed anatomical outcomes. Recurrence occurred in 20.0% of the prednisolone group and 26.7% of the PST/STA group (log-rank p = 0.68). Systemic corticosteroid-related metabolic complications were observed only in the prednisolone group, while PST/STA was associated with transient local discomfort and mild intraocular pressure elevation. No serious ocular complications occurred. In this retrospective, non-randomized cohort, no statistically significant differences were detected between oral prednisolone and PST/STA in the short-term clinical and anatomical outcomes assessed. Because treatment allocation was influenced by disease severity and systemic involvement, the sample size was small, no a priori sample-size calculation was performed, and the systemic corticosteroid regimen was abbreviated, these findings should not be interpreted as evidence of therapeutic equivalence or as establishing PST/STA as an alternative to systemic corticosteroid therapy. Prospective, adequately powered studies with standardized assessment of ocular and systemic disease severity are needed. ClinicalTrials.gov, NCT07405489. Registered 30 January 2026 (retrospectively registered), https://clinicaltrials.gov/study/NCT07405489 .

PMID 42934593
阅读全文 →
PubMedFrontiers in veterinary science2026-10-27

Fibrostenotic intestinal stenosis associated with chronic enteropathy in two cats: case report.

Choi Jiho J, Yang Seongmo S, Lee Yelim Y, Sung Yunjin Y et al.

Two cats presented with acute progressive vomiting. One cat (Case 1) received prednisolone for suspected chronic inflammatory enteropathy for 14 months. The cat showed hypoalbuminemia, hypocobalaminemia, small intestinal thickening, and focal jejunal stricture with severe proximal dilation on ultrasonography. Exploratory laparotomy confirmed the stricture, and histopathology revealed submucosal fibroplasia with mild lymphoplasmacytic enteritis. The cat died on postoperative day 12. Another cat (Case 2) showed proximal small intestinal obstruction on ultrasonography. A wide-margin resection of the obstructed lesion was performed. Histopathology revealed mild intestinal wall fibrosis with mesenteric inflammation. Masson's trichrome staining showed submucosal collagen bundles. Immunohistochemistry and clonality analysis by PCR for antigen receptor rearrangement supported the diagnosis of low-grade intestinal T-cell lymphoma. The cat recovered uneventfully and remained restenosis-free during prednisolone treatment for 12 months after surgery. Intestinal stenoses were identified during long-term medical management of chronic enteropathy. This suggests that the extent of the lesion and the surgical resection strategy could be relevant factors for management and prognosis.

PMID 42936481
阅读全文 →
PubMedAnimals : an open access journal from MDPI2026-10-27

Primary Erythrophagocytic Low-Grade Splenic T-Cell Lymphoma in a Cat: Clinical Case and Literature Review.

Barbetta Aurora A, Cremonini Valentina V, Antognoni Maria Teresa MT, Birettoni Francesco F et al.

Lymphoma is a common hematopoietic neoplasm in cats; yet hepatosplenic forms remain rare. This report describes a unique case of low-grade erythrophagocytic splenic T-cell lymphoma with suspected peripheral blood involvement in a six-year-old neutered male domestic shorthair cat. The patient presented with severe non-regenerative macrocytic normochromic anemia and moderate splenomegaly. Blood smears revealed mononucleated cells exhibiting erythrophagocytosis. Splenic cytology and flow cytometry were consistent with a reactive process, leading to a presumptive diagnosis of immune-mediated anemia. The condition proved refractory to immunosuppressive therapy with prednisolone and cyclosporine. After splenectomy, histopathology showed diffuse erythrophagocytosis and white pulp hyperplasia. Definitive diagnosis was achieved only by PARR analysis, which demonstrated a monoclonal T-cell receptor gene rearrangement within a polyclonal background. This confirmed a neoplastic T-cell population despite the mature morphology of the lymphocytes. Treatment with chlorambucil and prednisolone resulted in progressive resolution of the anemia. The cat remains alive 13 months after splenectomy. This case highlights the diagnostic challenges of low-grade lymphomas, in which reactive features can mask neoplasia, and underscores the critical role of PARR analysis in differentiating monoclonal T-cell proliferation from complex reactive processes in feline splenic disorders.

PMID 42939165
阅读全文 →
PubMedVeterinary sciences2026-10-27

Comparison of the Effects of 0.05% Difluprednate Ophthalmic Solution and 1% Prednisolone Acetate Ophthalmic Solution on Intraocular Inflammation Following Lens Surgery in Healthy Rabbits.

Okui Hiroaki H, Takishita Shoma S, Fuke Naoyuki N, Kaneko Yasuyuki Y et al.

Prednisolone acetate (PA) ophthalmic solution is used to treat post-cataract surgery uveitis. In humans, studies comparing difluprednate (DFBA) and PA ophthalmic solutions have reported the usefulness of DFBA. Herein, we compared the effects of PA and DFBA on uveitis following phacoemulsification in rabbits by evaluating anterior chamber flare values using a laser flare meter, anterior chamber flare grades using a slit-lamp microscope, posterior capsule opacification (PCO) formation, and histopathological findings. Anterior chamber flare values were highest on the first postoperative day in both groups, decreasing thereafter. Flare values were significantly lower in the DFBA group than in the PA group only on postoperative day 7; no significant between-group differences were observed at other measurement points. Flare grades were highest on the day after surgery in both groups and subsequently decreased, with no significant between-group differences. There were no significant differences in PCO area or the number of inflammatory cells in the iris, ciliary body, and choroid. These findings suggest that the suppressive effect of DFBA on uveitis following phacoemulsification in healthy rabbits is comparable to that of PA. Future studies should investigate the effects of DFBA ophthalmic solution in cataract surgery in rabbits and other animal species.

PMID 42944180
阅读全文 →
PubMedInternational journal of molecular sciences2026-10-27

Fidanacogene Elaparvovec Gene Therapy: Budesonide Treatment of a Late Decline in Factor IX Expression in a Patient with Hemophilia B.

Herbst Kerstin K, Pezeshkpoor Behnaz B, Klein Claudia C, Albert Thilo T et al.

Fidanacogene elaparvovec is an adeno-associated virus (AAV)-based gene therapy that enables endogenous factor IX (FIX) expression in hemophilia B, potentially eliminating the need for prophylactic FIX replacement. Post-treatment monitoring focuses on FIX durability, hepatic safety, and immune-mediated loss of expression. A 40-year-old man with severe hemophilia B received a single intravenous dose of fidanacogene elaparvovec in the phase 3 BENEGENE-2 trial (NCT03861273). FIX activity was assessed by one-stage and chromogenic assays. Liver enzymes, clinical parameters, and adverse events were monitored. Prednisolone was initiated for liver enzyme elevation and later switched to budesonide in response to declining FIX levels. Follow-up continued for 4 years. FIX activity peaked at week 6 (~30 IU/dL) and remained stable until week 16. Moderate ALT elevation (peak ~70 U/L) responded to prednisolone. Between weeks 22-28, FIX levels declined without ALT elevation. Budesonide (9 mg/day) was started at week 25 for 3 months and gradually tapered, stabilizing FIX activity at 10-20 IU/dL. This level has been maintained for 4 years without bleeding episodes or FIX replacement. Fidanacogene elaparvovec provided sustained, clinically meaningful FIX expression. Budesonide may offer an effective hepatocyte-targeted alternative to systemic corticosteroids while supporting long-term transgene expression.

PMID 42941822
阅读全文 →
PubMedCureus2026-10-27

Mixed Autoimmune Hemolytic Anemia as the Initial Manifestation of Systemic Lupus Erythematosus: A Case Report.

Iqbal Tariq T, Chivero Cleopatra C, Farhana Sharmin S

Mixed autoimmune hemolytic anemia (mAIHA) is a rare subtype of autoimmune hemolytic anemia (AIHA) characterized by the coexistence of warm (immunoglobulin G (IgG)) and cold (immunoglobulin M (IgM)) autoantibodies. It may occur as a primary disorder or secondary to underlying conditions, including systemic lupus erythematosus (SLE). We report the case of a 16-year-old female who presented with severe hemolytic anemia as the initial manifestation of SLE. On admission, her hemoglobin was 34 g/L with marked reticulocytosis and a positive direct antiglobulin test (DAT) demonstrating both IgG and IgM antibodies, confirming mAIHA. Immunological investigations revealed positive antinuclear antibody (ANA), anti-double-stranded DNA (anti-dsDNA) antibody, and anti-Smith antibody, supporting a diagnosis of SLE. At the time of the first presentation, she had no other clinical features suggestive of SLE. She was treated with blood transfusions and corticosteroids, resulting in significant improvement, and was discharged on a tapering prednisolone regimen. Shortly after, she was readmitted with a malar rash, arthralgia, joint swelling, nephrotic-range proteinuria, and worsening renal function. She was subsequently diagnosed with SLE complicated by lupus nephritis and recurrent AIHA. Following the rheumatology and nephrology review, she received intravenous methylprednisolone and was transferred to a tertiary care center for renal biopsy and further management. Renal biopsy demonstrated focal segmental glomerulosclerosis (FSGS). Further treatment with prednisolone, mycophenolate mofetil, intravenous belimumab, and hydroxychloroquine resulted in an excellent clinical response, with follow-up confirming remission. This case highlights mAIHA as a rare initial presentation of SLE and underscores the importance of early recognition, close monitoring, and multidisciplinary management, as patients presenting with AIHA may be at increased risk of developing lupus nephritis and other severe SLE-related complications.

PMID 42936060
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多prednisolone